Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat vs Best Available Therapy in Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea
2023-504865-21-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of bomedemstat in thrombocythemia (2 arms), sponsored by Merck & Co. Primary endpoint: Durable Clinicohematologic Response (DCHR) Rate. Planned start Mar 2024; status: authorised.
02
Drugs
bomedemstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on 2023-504865-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504865-21-00.